Evidence map›Paper›PMID 9689099›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America1998

A mutant cell line defective in response to double-stranded RNA and in regulating basal expression of interferon-stimulated genes.

D W Leaman, A Salvekar, R Patel, G C Sen, G R Stark

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. IRF-3-dependent, NFkappa B- and JNK-independent activation of the 561 and IFN-beta genes in response to double-stranded RNA.Proceedings of the National Academy of Sciences of the United States of America · 2002
    Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

D W LeamanDepartment of Molecular Biology, Lerner Research Institute, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA.
A Salvekar
R Patel
G C Sen
G R Stark
Cleveland Clinic · USCase Comprehensive Cancer Center

Funding

TELOMERASE INACTIVATION BY RNASE L SIGNALS CELL DEATHP01CA062220 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI LI, XIAOXIA · 1994 to 2020
$35.6M
NEW MUTANT CELL LINES DEFECTIVE IN INTERFERON SIGNALLINGF32AI008956 · NIAID · CLEVELAND CLINIC FOUNDATION · PI LEAMAN, DOUGLAS W · 1993 to 1995
–
NCI NIH HHS P01 CA062220NCI NIH HHS P01-CA62220NIAID NIH HHS F32 AI008956NIAID NIH HHS F32-AI 08956
6 · The paper itself

Abstract

Although much progress has been made in identifying the signaling pathways that mediate the initial responses to interferons (IFNs), much less is known about how IFN-stimulated genes (ISGs) are kept quiescent in untreated cells, how the response is sustained after the initial induction, and how ISG expression is down-regulated, even in the continued presence of IFN. We have used the cell sorter to isolate mutant cells with constitutively high ISG expression. A recessive mutant, P2.1, has higher constitutive ISG levels than the parental U4C cells, which do not respond to any IFN. Unexpectedly, P2.1 cells also are deficient in the expression of ISGs in response to double-stranded RNA (dsRNA). Electrophoretic mobility-shift assays revealed that the defect is upstream of the activation of the transcription factors NFkappaB and IFN regulatory factor 1. Analysis of the pivotal dsRNA-dependent serine/threonine kinase PKR revealed that the wild-type kinase is present and is activated normally in response to dsRNA in P2.1 cells. Together, these data suggest that the defect in P2.1 cells is either downstream of PKR or in a component of a distinct pathway that is involved both in activating multiple transcription factors in response to dsRNA and in regulating the basal expression of ISGs.

Indexed as

Cell LineCell SeparationeIF-2 KinaseEnzyme ActivationFlow CytometryGene Expression RegulationGenetic Complementation TestHumansInterferonsJanus Kinase 1Protein-Tyrosine KinasesRNA, Double-StrandedTranscription FactorseIF-2 KinaseInterferonsJAK1 protein, humanJanus Kinase 1Protein-Tyrosine KinasesRNA, Double-StrandedTranscription Factors

Identifiers

PMID9689099
PMCPMC21357
OpenAlexW2012588764

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.